Vascular access complications — from peripheral IV phlebitis to central line-associated bloodstream infections (CLABSIs) — represent both a patient safety crisis and a significant financial burden. The CDC estimates 28,000 CLABSI deaths annually in U.S. ICUs, with each infection costing $46,000–$68,000 in attributable healthcare costs. CMS eliminated CLABSI reimbursement for preventable cases in 2009, creating strong financial alignment with clinical quality. Our IV and vascular access catalog includes over 23,000 products from BD, Baxter, B.Braun, and ICU Medical.
CLABSI Prevention Bundle: The Five Elements
The CDC/IHI CLABSI prevention bundle, validated across thousands of ICUs worldwide, consists of five evidence-based elements that must be implemented simultaneously (bundle compliance, not element-by-element compliance, is the key metric): (1) hand hygiene before all line access; (2) maximal sterile barrier precautions during insertion (cap, mask, gown, sterile gloves, and full-body sterile drape); (3) chlorhexidine gluconate (CHG) skin antisepsis; (4) avoidance of femoral site when possible (subclavian preferred for lowest CLABSI rate); (5) daily review of line necessity with prompt removal when no longer indicated. Facilities implementing all five bundle elements concurrently achieve 65–70% CLABSI rate reduction, compared to minimal improvement with individual element implementation alone.
CHG-Impregnated Dressings: Evidence for Routine Use
Chlorhexidine-impregnated transparent dressings for central venous catheter (CVC) sites — including 3M Tegaderm CHG and BD ChloraPrep with dressing — have demonstrated 60% reduction in catheter-related bloodstream infections vs standard transparent dressings in meta-analysis. The CDC Tier 2 CLABSI prevention recommendation (for units with CLABSI rates above targets despite standard bundle implementation) includes CHG-impregnated dressings. CVC dressing changes should be performed every 7 days for transparent film dressings (or whenever soiled/loosened) using sterile technique with CHG antisepsis. Our vascular access section includes CHG dressings, securement devices, and central line kits.
Peripheral IV Phlebitis Prevention
Peripheral intravenous catheter (PIVC) phlebitis — inflammation of the vein wall from chemical, mechanical, or bacterial causes — affects 20–80% of IV catheters during their dwell. Prevention strategies include: using the smallest gauge catheter appropriate for therapy, avoiding antecubital veins (high flexion movement increases mechanical phlebitis), rotating sites every 72–96 hours, and using inline filters for infusions with high phlebitis potential. BD Venflon Pro Safety catheters and Terumo Surflash PIVCs with integrated safety mechanisms are in our peripheral access catalog.
Needleless Connector Hygiene
Scrub-the-hub protocols — vigorous 15-second friction scrub of needleless connectors with 70% isopropyl alcohol before each access — reduce intraluminal contamination, a primary pathway for CLABSIs not preventable by skin antisepsis alone. Antimicrobial caps (endcaps containing 70% isopropyl alcohol that passively disinfect connectors between accesses) have shown 60–85% CLABSI reduction in multiple ICU studies and are now recommended by SHEA and IDSA as standard care. Curos Port Protectors and SwabCap from ICU Medical are available through our vascular access catalog.
